ArticleNPJ precision oncology2021

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.

Maurício Fernando Silva Almeida Ribeiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.